- Active not recruitingPHASE2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
This study is looking at new ways to treat advanced liver and bile duct cancers. It tests new medicines, called immunomodulators, either on their own or alongside other cancer drugs, to see how well they work and if they are safe.
For: Hepatocellular Carcinoma · Biliary Tract CancerUnited States · China · Hong Kong - RecruitingPHASE3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
This study is testing a new medicine, volrustomig, for people with a type of head and neck cancer that hasn't spread and wasn't removed by surgery. It aims to see if volrustomig helps prevent the cancer from coming back after standard treatment like chemotherapy and radiotherapy.
For: Locally Advanced Head and Neck Squamous Cell CarcinomaUnited States · Austria · Belgium - RecruitingPHASE2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
This study looks at a new drug, Dato-DXd, by itself and with other treatments for different advanced cancers like those affecting the stomach, ovaries, and prostate. It checks if the treatment is safe and effective.
For: Endometrial Cancer · Gastric Cancer · Metastatic Castration-resistant Prostate CancerUnited States · Canada · China - RecruitingPHASE2
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
This study is looking into a new medicine called Volrustomig for various advanced cancers, including cervical, head and neck, oesophageal, and mesothelioma. It aims to see how well it works and if it's safe, both on its own and with standard chemotherapy.
For: Sub-study 1 Cervical Cancer (Volrustomig Monotherapy) · Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy) · Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)United States · Australia · Brazil - Active not recruitingPHASE3
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
This study is testing two different combinations of medicines, volrustomig plus chemotherapy, or pembrolizumab plus chemotherapy, for people with an advanced type of lung cancer. The aim is to see which combination is safer and works better as a first treatment.
For: Metastatic Non-small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE2
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
This study looks at new drug combinations before and after surgery for early-stage lung cancer. It aims to see if these treatments are safe and work well to help people with non-small cell lung cancer.
For: Non-small Cell Lung CancerUnited States · Belgium · Canada - RecruitingPHASE2
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
This study is testing new treatments for a type of advanced bowel cancer that has spread. It compares a new drug called Volrustomig combined with standard chemotherapy and another drug (FOLFIRI and Bevacizumab) against the standard treatment alone, to see if adding Volrustomig is safe and effective.
For: Metastatic Colorectal CancerUnited States · Australia · Canada - RecruitingPHASE2
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
This study is testing new combinations of medicines for advanced stomach or food pipe cancer that has spread or can't be removed by surgery. It aims to see how well they work and if they are safe. Researchers want to find better ways to treat this type of cancer.
For: Gastric CancerUnited States · China · Japan - RecruitingPHASE2
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
This study looks at new treatments for advanced stomach or oesophageal cancer with a specific protein called HER2. We're testing a new drug, trastuzumab deruxtecan, by itself or with other common cancer medicines to see if it's safe and effective.
For: Gastric CancerUnited States · Brazil · Canada - Active not recruitingPHASE3
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
This study compares a new treatment, Volrustomig combined with standard chemotherapy, against existing treatments for advanced mesothelioma. It aims to see if the new combination is safer and more effective for patients whose cancer can't be removed by surgery.
For: Unresectable Pleural MesotheliomaUnited States · Australia · Belgium